Eliem Therapeutics Income from Continuous Operations 2021-2024 | CLYM
Eliem Therapeutics income from continuous operations from 2021 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Eliem Therapeutics Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$-35 |
| 2022 |
$-45 |
| 2021 |
$-47 |
| 2020 |
$-21 |
Eliem Therapeutics Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-06-30 |
$-55 |
| 2024-03-31 |
$-2 |
| 2023-12-31 |
$-4 |
| 2023-09-30 |
$-4 |
| 2023-06-30 |
$-5 |
| 2023-03-31 |
$-22 |
| 2022-12-31 |
$-8 |
| 2022-09-30 |
$-10 |
| 2022-06-30 |
$-15 |
| 2022-03-31 |
$-13 |
| 2021-12-31 |
$-11 |
| 2021-09-30 |
$-10 |
| 2021-06-30 |
$-9 |
| 2021-03-31 |
$-19 |
| 2020-12-31 |
|
| 2020-09-30 |
$-2 |
| 2020-06-30 |
$-2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
